Different Infection Risks for MS Treatments Different Infection Risks for MS Treatments
New study results suggest rituximab has a higher risk of serious infections than fingolimod or natalizumab, but a lower risk of herpetic infections.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - October 10, 2019 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
New Data on Natalizumab During Pregnancy in MS New Data on Natalizumab During Pregnancy in MS
Women with multiple sclerosis who continued to receive the drug during pregnancy had a much lower risk of relapses, according to a new Italian observational study.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - September 19, 2019 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
Sandoz announces global deal to commercialize proposed biosimilar natalizumab, a key multiple sclerosis medicine
Sandoz, a Novartis division and a global leader in biosimilars, announced that it has entered into a global commercialization agreement for a proposed natalizumab biosimilar. The medicine is in Phase III clinical development for the treatment of relapsing-remitting multiple sclerosis (RRMS). (Source: World Pharma News)
Source: World Pharma News - September 5, 2019 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news
Novartis licenses multiple sclerosis biosim
The company ' s Sandoz unit has licensed a version of natalizumab from Polpharma Biologics (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - September 3, 2019 Category: Pharmaceuticals Source Type: news
Novartis's Sandoz licenses proposed multiple sclerosis biosimilar
Swiss drugmaker Novartis's Sandoz division has licensed from Polpharma Biologics a proposed biosimilar version of multiple sclerosis drug natalizumab, the companies said on Tuesday without giving financial details of the accord. (Source: Reuters: Health)
Source: Reuters: Health - September 3, 2019 Category: Consumer Health News Tags: healthNews Source Type: news
FDA Drug Safety Communication: New risk factor for Progressive Multifocal Leukoencephalopathy (PML) associated with Tysabri (natalizumab)
[01-20-2012] The U.S. Food and Drug Administration (FDA) is informing the public that testing positive for anti-JC virus (JCV) antibodies has been identified as a risk factor for progressive multifocal leukoencephalopathy (PML). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 26, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Risk for Conversion of MS Varies With Different Therapies
WEDNESDAY, Jan. 16, 2019 -- For relapsing-remitting multiple sclerosis (MS), the risk for conversion to secondary progressive MS is lower with initial treatment with fingolimod, alemtuzumab, or natalizumab versus glatiramer acetate or interferon... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 16, 2019 Category: Pharmaceuticals Source Type: news
Switching to Alemtuzumab in MS, Keep Washout to a Minimum Switching to Alemtuzumab in MS, Keep Washout to a Minimum
Two new studies of patients switching from natalizumab or fingolimod to alemtuzumab suggest that shorter washout periods are better to reduce disease reactivation.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 24, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
Natalizumab or Fingolimod After First-Line Drugs in MS? Natalizumab or Fingolimod After First-Line Drugs in MS?
A new propensity score analysis suggests natalizumab may have the edge over fingolimod for patients who experience relapse on first-line drugs, especially patients with more active disease.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 11, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
Asymptomatic Progressive Multifocal Leukoencephalopathy Asymptomatic Progressive Multifocal Leukoencephalopathy
This case underscores that clinical vigilance and routine MRI surveillance is important for MS patients at high risk for developing natalizumab-associated PML, even if they are asymptomatic.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 12, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news
Natalizumab cost effective versus fingolimod for RRMS
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - June 1, 2018 Category: Drugs & Pharmacology Source Type: news
MS: New Dosing, A New Withdrawal MS: New Dosing, A New Withdrawal
Cutting the risk for natalizumab-related PML, update on disability outcomes with ibudilast, and daclizumab pulled from the global market.Medscape Neurology (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - April 5, 2018 Category: Drugs & Pharmacology Tags: Neurology & Neurosurgery Commentary Source Type: news
An MS Drug Update An MS Drug Update
Cutting the risk for natalizumab-related PML, update on disability outcomes with ibudilast, and daclizumab pulled from the global market.Medscape Neurology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 29, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery Commentary Source Type: news
JC Virus May Be Undetectable in CSF in Some Patients With Small PML Lesions JC Virus May Be Undetectable in CSF in Some Patients With Small PML Lesions
JC virus (JCV) may be undetectable in the cerebrospinal fluid (CSF) of natalizumab-treated patients with multiple sclerosis (MS) who have small progressive multifocal leukoencephalopathy (PML) lesions, according to a retrospective study.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - March 14, 2018 Category: Pathology Tags: Neurology & Neurosurgery News Source Type: news
Comunicado de la FDA sobre la seguridad de los medicamentos: Nuevo factor de riesgo para la leucoencefalopat ía multifocal progresiva (PML por sus siglas en inglés) relacionado con Tysabri (natalizumab)
El 20 de enero del 2012, la Administraci ón de Alimentos y Medicamentos de Estados Unidos (FDA por sus siglas en inglés) informó al público que ha identificado como factor de riesgo para la leucoencefalopatía multifocal progresiva (PML por sus siglas en inglés) la detección en pruebas de anticuerpos contra el virus JC. PML es una in fección poco común pero grave del cerebro relacionada con el uso de Tysabri (natalizumab) para el tratamiento de esclerosis múltiple o enfermedad de Crohn. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 13, 2018 Category: Drugs & Pharmacology Source Type: news
